Abbas Deesawala Email and Phone Number

- Driving the key strategic initiatives of the GCEO across strategy, M&A, business development, new market entry, manufacturing excellence for the Cooper group of companies across geographies - ideation to completion.- Business Development for GCC and SSA across BUs (IN and OUT)- Ensuring the seamless flow of projects across the value chain, end to end.

- Commercial Lead for SEA Markets (PH, HK, SG, MY, ID, VN) - P&L of ~$25mn - Responsible for day to day Commercial Operations as well as Strategic BD, Portfolio, Marketing

• Business development, In-licensing and New market entry for Morocco's leading pharmaceutical player, Cooper Pharma, as it looks to expand its footprint across MEA.• In-licensing generics, 505 b2s and NCEs across Africa & Middle East.• Evaluating tech transfer opportunities to our facilities in Morocco, Ivory Coast and Rwanda for local manufacturing. • Crystalizing the product pipeline in line with the organization’s 5 year growth strategy.• Evaluating new market entry opportunities.

• Head of Portfolio and (interim head) BD functions for Alvogen APAC , based in Taipei, Taiwan - $250mn business.• Key responsibilities included bringing novelty and high entry barrier to our products and business: Identifying unique incremental innovation projects, NCEs and new therapy entry through M&A, BD or in-house technologies.• Chairing cross functional meetings across Medical, PMO, R&D, Finance, Sales & Marketing, BD, IP, RA t to align and onboard all stakeholders on critical projects.• Liaising with external stakeholders like KOL’s, during the bottom-up evaluation phase to clearly define expected outcomes from a project.

- Responsible for the growth story of the ~$500mn Africa BU at Cipla.- Entrusted with developing long-term region-specific differentiated portfolio strategies for South Africa, Sub-Saharan Africa and the Global Access markets and making data-driven recommendations on how and where Cipla should play.- Key stakeholder in critically evaluating both in-house and licensing/M&A product opportunities for a go/no-go decision to ensure the right mix of simple and complex products to enhance the base business in the short-term as well as long-term.- Ensuring successful on-time delivery of new products from bench to market by constant cross-functional collaboration with Marketing teams, API and Formulations R&D, Regulatory, Clinical, IP, Manufacturing.- Future-proofing products by foreseeing and solving for key risks like API supply, capacity constraint, etc. to ensure minimal disruption to business as usual.- Collecting market insights and intelligence from primary as well as secondary sources to improve new product performance predictability.

- Responsible for anchoring Formulations product selection across all Emerging markets(Africa, ANZ, APAC, LATAM, Middle East, Russia+CIS) of Cipla:-- Leveraging the pipeline of Regulated Markets to emerging markets (for Cipla and JV's) to ensurevalue maximization.- Collaborating across BD teams, R&D teams including API and Formulations, Regulatory, Clinical, IP to finalize the current/future portfolio.- Developing Region-specific portfolio strategies, especially for more backward economies like Sub-Saharan Africa and making data-driven recommendations on how and where Cipla should play.- Laying out the business plan for products to be selected and products in the pipeline.- Responsible for ensuring timely filing all products under development.- Collecting market insights and intelligence from primary as well as secondary sources.- Developing a comprehensive database for management of product information across all identified formulation markets.

- Primarily handling Product Portfolio Management (Generics - NPNC) for US and EU Markets:- - Detailed monitoring of our current pipeline molecules in their developmental stage (timeline to filing and expenses incurred) to ensure that eventual launch timelines are met. - Selecting new molecules for induction into the pipeline after a thorough feasibility analysis from alegal, business and formulations perspective, based on availability of resources and allocation offunds.- Forecasting revenues for selected molecules and preparing business cases to estimate project viability.- Pharma market and competitor analysis, done using a combination of 4 key databases: - IMS, Newport, Walters-Kluwer & IMS Patent Life Cycle.- Liaison between API-R&D, F-R&D, IPM and Strategy teams for collective decision-making on potential therapy areas that can be entered into.- Liaison with front-end office in USA to better understand US market dynamics, for expected revenue generation.- Financial Analysis of competitors to get deeper insight on their functioning.

Trainee at the R&D facility of the Integrated Product Development Organization (IPDO) division. Worked on formulating an anti-diabetic drug with a project titled - “Formulation, Evaluation and Systematic Optimization of Oral Dosage Forms Using Design of Experiments (DoE)”.

Worked in bioAgriculture and bioNutrition departments. Hands-on experience in solvent extraction, DPPH anti-oxidant assay and streak plating. Observed: the working of 2D Gel Electrophoresis, MALDI Mass Spectrometry, oil extraction from maize seeds and a variety of cell lines and cell culture media.

Clinical diagnostic lab. Exposure to 9 departments: Phlebotomy, Biochemistry, Immunology, Clinical Pathology, Hematology, HLA, Histopathology, Serology and Microbiology. Hands-on experience in blood testing (ABO typing), urine analysis, blood cell count (hemocytometry) and blood glucose testing (OGTT).